Concepedia

Jonathan Matz

JM

Statistics

Publications

19

Citations

2.6K

H-Index

16

Active since

1994

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Research Triangle Park Foundation

Bernstein Clinical Research Center

Allergy, Asthma and Clinical Research Center

Creighton University

Jonathan Matz is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacology, and asthma pharmacotherapy.

ORCID

Publications per year

1994–2023

19

Publications

19

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

M. Solèr, Jonathan Matz, Robert G. Townley et al. · European Respiratory Journal · 2001 · 826 citations · Full text

, , +17

Montelukast for Chronic Asthma in 6- to 14-Year-Old Children

Barbara Knorr, Jonathan Matz, Jonathan A. Bernstein et al. · JAMA · 1998 · 484 citations

, , +13

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

, , +6

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 224 citations · Full text

, , +8

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Roland Buhl, M. Solèr, Jonathan Matz et al. · European Respiratory Journal · 2002 · 180 citations · Full text

, , +15

1–5 of 19